OLIKOS Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients who Transition from Intravenous Anti-CD20 Therapy

被引：0
|
作者：
Hua, Le H. [1 ]
Alvarez, Enrique [2 ]
Foley, John [3 ]
Henry, Roland G. [4 ]
Brown, Joel [5 ]
Camacho, Elizabeth [5 ]
Meng, Xiangyi [5 ]
Ziehn, Marina [6 ]
Brown, Brandon [5 ]
Greenberg, Benjamin M. [7 ]
机构：
[1] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA
[2] Univ Colorado, Boulder, CO 80309 USA
[3] Rocky Mt Multiple Sclerosis Clin, Salt Lake City, UT USA
[4] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA
[5] Novartis Pharmaceut, Basel, Switzerland
[6] Novartis Pharma AG, Basel, Switzerland
[7] UT Southwestern Med Ctr, Dallas, TX USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
4567
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Olikos study design: exploring maintained ofatumumab efficacy in relapsing ms patients who transition from intravenous anti-cd20 therapy
    Greenberg, B.
    Alvarez, E.
    Foley, J.
    Henry, R.
    Brown, J.
    Camacho, E.
    Meng, X.
    Ziehn, M.
    Brown, B.
    Hua, L. H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 226 - 226
  • [2] Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Houtsma, Erik
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1167 - 1168
  • [3] OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Piccolo, Rebecca
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1101 - 1102
  • [4] Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab
    Chen, Lucia Y.
    Shah, Raakhee
    Cwynarski, Kate
    Lambert, Jonathan
    McNamara, Christopher
    Mohamedbhai, Sajir G.
    Virchis, Andres
    Townsend, William
    D'Sa, Shirley
    Ardeshna, Kirit M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) : 462 - 465
  • [5] Safety and efficacy of cladribine therapy following a treatment with anti-CD20 compounds in relapsing multiple sclerosis patients: a pilot study
    Sacco, R.
    Disanto, G.
    Pravata, E.
    Gobbi, C.
    Zecca, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 852 - 852
  • [6] Brain-derived blood extracellular vesicles as potential biomarkers in multiple sclerosis (MS): Pilot results from relapsing MS patients receiving anti-CD20 therapy
    Anandan, Shamundeeswari
    Feliciello, Giancarlo
    Werner-Klein, Melanie
    Stojanovic, Natasa
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 305 - 306
  • [7] Rates and predictors of serious infections in MS and NMOSD patients treated with anti-CD20 therapy
    Mears, V.
    Jakubecz, C.
    Serra, A.
    Abboud, H.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 357 - 357
  • [8] Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy
    Vo, A. A.
    Jordan, S. C.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 178 : 48 - 51
  • [9] Rates and Predictors of Serious Infections in MS and NMOSD Patients treated with Anti-CD20 Therapy
    Abboud, Hesham
    Mears, Veronica
    Jakubecz, Collin
    Serra, Alessandro
    NEUROLOGY, 2023, 100 (17)
  • [10] Anti-cd20 therapy interferes with the immune response to the hepatitis b virus vaccine in ms patients
    Otero-Romero, S.
    Cardenas-Robledo, S.
    Rodriguez, M.
    Uriona, S.
    Rando, A.
    Vidal-Jordana, A.
    Esperalba, J.
    Del Amo, E.
    Rodrigo-Pendas, J.
    Campins, M.
    Martinez, X.
    Tintore, M.
    Montalban, X.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 260 - 260
12345